Your browser doesn't support javascript.
loading
Severity of COVID-19 among Hospitalized Patients: Omicron Remains a Severe Threat for Immunocompromised Hosts.
Nevejan, Louis; Ombelet, Sien; Laenen, Lies; Keyaerts, Els; Demuyser, Thomas; Seyler, Lucie; Soetens, Oriane; Van Nedervelde, Els; Naesens, Reinout; Geysels, Dieter; Verstrepen, Walter; Cattoir, Lien; Martens, Steven; Michel, Charlotte; Mathieu, Elise; Reynders, Marijke; Evenepoel, Anton; Hellemans, Jorn; Vanhee, Merijn; Magerman, Koen; Maes, Justine; Matheeussen, Veerle; Boogaerts, Hélène; Lagrou, Katrien; Cuypers, Lize; André, Emmanuel.
Afiliación
  • Nevejan L; Department of Laboratory Medicine, National Reference Center for Respiratory Pathogens, UZ Leuven-University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.
  • Ombelet S; Department of Laboratory Medicine, National Reference Center for Respiratory Pathogens, UZ Leuven-University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.
  • Laenen L; KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical Microbiology, 3000 Leuven, Belgium.
  • Keyaerts E; Department of Laboratory Medicine, National Reference Center for Respiratory Pathogens, UZ Leuven-University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.
  • Demuyser T; KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical Microbiology, 3000 Leuven, Belgium.
  • Seyler L; KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical Microbiology, 3000 Leuven, Belgium.
  • Soetens O; Department of Microbiology and Infection Control, Vrije Universiteit Brussel (VUB), UZ Brussel-University Hospitals Brussels, 1090 Brussels, Belgium.
  • Van Nedervelde E; Center for Neurosciences, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium.
  • Naesens R; Department of Internal Medicine and Infectious Diseases, Vrije Universiteit Brussel (VUB), UZ Brussel-University Hospitals Brussels, 1090 Brussels, Belgium.
  • Geysels D; Department of Microbiology and Infection Control, Vrije Universiteit Brussel (VUB), UZ Brussel-University Hospitals Brussels, 1090 Brussels, Belgium.
  • Verstrepen W; Department of Internal Medicine and Infectious Diseases, Vrije Universiteit Brussel (VUB), UZ Brussel-University Hospitals Brussels, 1090 Brussels, Belgium.
  • Cattoir L; Department of Medical Microbiology, Department of infection prevention and control, ZNA Middelheim, 2020 Antwerp, Belgium.
  • Martens S; Department of Medical Microbiology, Department of infection prevention and control, ZNA Middelheim, 2020 Antwerp, Belgium.
  • Michel C; Department of Medical Microbiology, Department of infection prevention and control, ZNA Middelheim, 2020 Antwerp, Belgium.
  • Mathieu E; Clinical Laboratory of Microbiology, OLV Hospital, 9300 Aalst, Belgium.
  • Reynders M; Clinical Laboratory of Microbiology, OLV Hospital, 9300 Aalst, Belgium.
  • Evenepoel A; Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles, Université Libre de Bruxelles, 1000 Brussels, Belgium.
  • Hellemans J; Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles, Université Libre de Bruxelles, 1000 Brussels, Belgium.
  • Vanhee M; Department of Laboratory Medicine-Medical Microbiology, AZ Sint Jan Brugge-Oostende, 8000 Brugge, Belgium.
  • Magerman K; Department of Laboratory Medicine-Medical Microbiology, AZ Sint Jan Brugge-Oostende, 8000 Brugge, Belgium.
  • Maes J; Department of Laboratory Medicine-Medical Microbiology, AZ Sint Jan Brugge-Oostende, 8000 Brugge, Belgium.
  • Matheeussen V; Department of Laboratory Medicine-Medical Microbiology, AZ Sint Jan Brugge-Oostende, 8000 Brugge, Belgium.
  • Boogaerts H; Clinical Laboratory, Jessa Hospital, 3500 Hasselt, Belgium.
  • Lagrou K; Clinical Laboratory, Jessa Hospital, 3500 Hasselt, Belgium.
  • Cuypers L; Department of Microbiology, University Hospital Antwerp, 2650 Antwerp, Belgium.
  • André E; Department of Microbiology, University Hospital Antwerp, 2650 Antwerp, Belgium.
Viruses ; 14(12)2022 12 08.
Article en En | MEDLINE | ID: mdl-36560741
The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in the general population in the context of a relatively high immunity gained through the early waves of coronavirus disease 19 (COVID-19), and vaccination campaigns. Despite this context, a significant number of patients were hospitalized, and identifying the risk factors associated with severe disease in the Omicron era is critical for targeting further preventive, and curative interventions. We retrospectively analyzed the individual medical records of 1501 SARS-CoV-2 positive hospitalized patients between 13 December 2021, and 13 February 2022, in Belgium, of which 187 (12.5%) were infected with Delta, and 1036 (69.0%) with Omicron. Unvaccinated adults showed an increased risk of moderate/severe/critical/fatal COVID-19 (crude OR 1.54; 95% CI 1.09-2.16) compared to vaccinated patients, whether infected with Omicron or Delta. In adults infected with Omicron and moderate/severe/critical/fatal COVID-19 (n = 323), immunocompromised patients showed an increased risk of in-hospital mortality related to COVID-19 (adjusted OR 2.42; 95% CI 1.39-4.22), compared to non-immunocompromised patients. The upcoming impact of the pandemic will be defined by evolving viral variants, and the immune system status of the population. The observations support that, in the context of an intrinsically less virulent variant, vaccination and underlying patient immunity remain the main drivers of severe disease.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Humans Idioma: En Revista: Viruses Año: 2022 Tipo del documento: Article País de afiliación: Bélgica

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Humans Idioma: En Revista: Viruses Año: 2022 Tipo del documento: Article País de afiliación: Bélgica